Use of Pulmonary Arterial Hypertension-specific Therapy in Overweight or Obese Patients with Obstructive Sleep Apnea and Pulmonary Hypertension

Overview

Journal Pulm Circ

Publisher Wiley

Specialty Pulmonary Medicine

Date 2014 Jul 10

PMID 25006443

Authors

Adil Shujaat

Jason Bellardini

Ankur Girdhar

Abubakr A Bajwa

Affiliations

Soon will be listed here.

Abstract

Pulmonary hypertension (PH) in overweight or obese patients with obstructive sleep apnea (OSA) may be multifactorial. The effect of pulmonary artery hypertension (PAH)-specific drugs on PH and exercise capacity in such patients is unknown. We performed a retrospective review of overweight or obese patients with OSA and PH who were treated with PAH-specific therapy in our PH clinic. We identified 9 female and 2 male patients. The mean age ± SD was 54.9 ± 9.3 years. The mean pulmonary artery pressure at the time of diagnosis of PH was 39.8 ± 16.1 mmHg. The right atrial pressure was 11.1 ± 4.5 mmHg, the pulmonary artery wedge pressure was 14.1 ± 2.9 mmHg, the cardiac index was 2.6 ± 0.5 L/min/m(2), and the pulmonary vascular resistance index was 10.6 ± 7.1 Wood units/m(2). The indications for use of PAH-specific therapy were dyspnea in association with right heart failure (n = 4), persistent PH despite compliance with nocturnal positive airway pressure (PAP) therapy (n = 4), or inability to tolerate PAP therapy (n = 3). PH was treated with an endothelin receptor antagonist (n = 8) or a phosphodiesterase-5 inhibitor (n = 3). The 6-minute walk distance (6MWD) improved significantly, from 234 ± 49.7 to 258 ± 54.6 m (24 m [95% confidence interval (CI): 6.5-341.5 m]; P = 0.014) over a period of 4.4 ± 1.8 months (n = 8) and from 241.7 ± 48.5 to 289.9 ± 91 m (48 m [95% CI: 5.5-90.8 m]; P = 0.033) in those with a longer follow-up period of 12.1 ± 6.4 months (n = 7). The systolic pulmonary artery pressure dropped significantly, from 64 ± 25.2 to 42 ± 10.4 mmHg (22 mmHg [95% CI: 4-40 mmHg]; P = 0.024) over a period of 6.1 ± 4.1 months (n = 7). In conclusion, PAH-specific therapy resulted in significant improvement in both PH and 6MWD.

References

Wall H, Smith C, Hubbard R . Body mass index and obstructive sleep apnoea in the UK: a cross-sectional study of the over-50s. Prim Care Respir J. 2012; 21(4):371-6. PMC: 6548036. DOI: 10.4104/pcrj.2012.00053. View

Shujaat A, Bajwa A, Cury J . Pulmonary Hypertension Secondary to COPD. Pulm Med. 2012; 2012:203952. PMC: 3437672. DOI: 10.1155/2012/203952. View

Sajkov D, Wang T, Saunders N, Bune A, McEvoy R . Continuous positive airway pressure treatment improves pulmonary hemodynamics in patients with obstructive sleep apnea. Am J Respir Crit Care Med. 2002; 165(2):152-8. DOI: 10.1164/ajrccm.165.2.2010092. View

Weaver T, Kribbs N, Pack A, Kline L, Chugh D, Maislin G . Night-to-night variability in CPAP use over the first three months of treatment. Sleep. 1997; 20(4):278-83. DOI: 10.1093/sleep/20.4.278. View

Krieger J, Sforza E, Apprill M, Lampert E, Weitzenblum E, Ratomaharo J . Pulmonary hypertension, hypoxemia, and hypercapnia in obstructive sleep apnea patients. Chest. 1989; 96(4):729-37. DOI: 10.1378/chest.96.4.729. View

Sforza E, Laks L, Grunstein R, Krieger J, Sullivan C . Time course of pulmonary artery pressure during sleep in sleep apnoea syndrome: role of recurrent apnoeas. Eur Respir J. 1998; 11(2):440-6. DOI: 10.1183/09031936.98.11020440. View

Simonneau G, Robbins I, Beghetti M, Channick R, Delcroix M, Denton C . Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009; 54(1 Suppl):S43-S54. DOI: 10.1016/j.jacc.2009.04.012. View

Lattimore J, Wilcox I, Adams M, Kilian J, Celermajer D . Treatment of obstructive sleep apnoea leads to enhanced pulmonary vascular nitric oxide release. Int J Cardiol. 2007; 126(2):229-33. DOI: 10.1016/j.ijcard.2007.04.001. View

Karkoulias K, Lykouras D, Sampsonas F, Drakatos P, Canova S, Tsoukalas G . The role of Endothelin-1 in obstructive sleep apnea syndrome and pulmonary arterial hypertension: pathogenesis and Endothelin-1 antagonists. Curr Med Chem. 2010; 17(11):1059-66. DOI: 10.2174/092986710790820624. View

10.

Minai O, Ricaurte B, Kaw R, Hammel J, Mansour M, McCarthy K . Frequency and impact of pulmonary hypertension in patients with obstructive sleep apnea syndrome. Am J Cardiol. 2009; 104(9):1300-6. DOI: 10.1016/j.amjcard.2009.06.048. View

11.

Alchanatis M, Tourkohoriti G, Kakouros S, Kosmas E, Podaras S, Jordanoglou J . Daytime pulmonary hypertension in patients with obstructive sleep apnea: the effect of continuous positive airway pressure on pulmonary hemodynamics. Respiration. 2002; 68(6):566-72. DOI: 10.1159/000050574. View

12.

Barst R, Gibbs J, Ghofrani H, Hoeper M, McLaughlin V, Rubin L . Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2009; 54(1 Suppl):S78-S84. PMC: 3686287. DOI: 10.1016/j.jacc.2009.04.017. View

13.

Badesch D, Raskob G, Elliott C, Krichman A, Farber H, Frost A . Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2009; 137(2):376-87. DOI: 10.1378/chest.09-1140. View

14.

Kessler R, Chaouat A, Schinkewitch P, Faller M, Casel S, Krieger J . The obesity-hypoventilation syndrome revisited: a prospective study of 34 consecutive cases. Chest. 2001; 120(2):369-76. DOI: 10.1378/chest.120.2.369. View

15.

Wang Z, Li A, Guo Q, Zhang J, An Q, Guo Y . Effects of cyclic intermittent hypoxia on ET-1 responsiveness and endothelial dysfunction of pulmonary arteries in rats. PLoS One. 2013; 8(3):e58078. PMC: 3589442. DOI: 10.1371/journal.pone.0058078. View

16.

Arias M, Garcia-Rio F, Alonso-Fernandez A, Martinez I, Villamor J . Pulmonary hypertension in obstructive sleep apnoea: effects of continuous positive airway pressure: a randomized, controlled cross-over study. Eur Heart J. 2006; 27(9):1106-13. DOI: 10.1093/eurheartj/ehi807. View

17.

Bady E, Achkar A, Pascal S, Orvoen-Frija E, Laaban J . Pulmonary arterial hypertension in patients with sleep apnoea syndrome. Thorax. 2000; 55(11):934-9. PMC: 1745626. DOI: 10.1136/thorax.55.11.934. View

18.

Gilbert C, Brown M, Cappelleri J, Carlsson M, McKenna S . Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil. Chest. 2008; 135(1):137-142. DOI: 10.1378/chest.07-0275. View

19.

Weitzenblum E, Chaouat A, Canuet M, Kessler R . Pulmonary hypertension in chronic obstructive pulmonary disease and interstitial lung diseases. Semin Respir Crit Care Med. 2009; 30(4):458-70. DOI: 10.1055/s-0029-1233315. View

20.

ENSON Y, Giuntini C, Lewis M, MORRIS T, FERRER M, Harvey R . THE INFLUENCE OF HYDROGEN ION CONCENTRATION AND HYPOXIA ON THE PULMONARY CIRCULATION. J Clin Invest. 1964; 43:1146-62. PMC: 289596. DOI: 10.1172/JCI104999. View